GlassScriptPhysician profile
Jessica Banning
NPI 1083383731
$3,813.04
in general payments reported to CMS, 2019-2025
26 companies · $18.93 in 2025
The $18.93 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,541 · 2023: $1,929 · 2024: $325 · 2025: $18.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.76 |
| Education | $117.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $608.91 | 2022-2024 | |
| Novo Nordisk INC | $529.88 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $414.68 | 2022-2024 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.61 | 2022-2023 | Jardiance, Tradjenta, Synjardy |
| Glaxosmithkline, LLC. | $213.50 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $192.62 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $192.52 | 2022-2024 | Rexulti |
| Lilly USA, LLC | $182.52 | 2022-2023 | Trulicity, Mounjaro, Jardiance |
| Sumitomo Pharma America, INC. | $167.14 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $117.95 | 2022-2023 | |
| Lundbeck LLC | $116.65 | 2022-2023 | Rexulti |
| Amgen INC. | $115.11 | 2022-2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $114.72 | 2022 | |
| Corcept Therapeutics | $102.72 | 2023 | Korlym |
| Sunovion Pharmaceuticals INC. | $86.81 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.09 | 2023-2024 | |
| Vivus LLC | $78.61 | 2024 | Qsymia |
| Amarin Pharma, INC. | $46.55 | 2022-2023 | |
| Exact Sciences Corporation | $36.24 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $25.11 | 2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $20.01 | 2022 | |
| Abbott Laboratories | $18.68 | 2023 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $18.54 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.28 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.98 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.61 | 2023 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Banning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.